Title |
Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy
|
---|---|
Published in |
Leukemia & Lymphoma, April 2023
|
DOI | 10.1080/10428194.2023.2196593 |
Pubmed ID | |
Authors |
Naveen Pemmaraju, Prithviraj Bose, Raajit Rampal, Aaron T. Gerds, Angela Fleischman, Srdan Verstovsek |
Abstract |
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly, abnormal cytokine expression, cytopenias, and progressive bone marrow fibrosis. The disease often manifests with burdensome symptoms and is associated with reduced survival. Ruxolitinib, an oral Janus kinase (JAK) 1 and JAK2 inhibitor, was the first agent approved for MF. As a first-in-class targeted treatment, ruxolitinib approval transformed the MF treatment approach and remains standard of care. In addition, targeted inhibition of JAK1/JAK2 signaling, a key molecular pathway underlying MF pathogenesis, and the large volume of literature evaluating ruxolitinib, have led to a better understanding of the disease and improved management in general. Here we review ruxolitinib efficacy in patients with MF in the 10 years following approval, including demonstration of clinical benefit in the phase 3 COMFORT-I/II trials, real-world evidence, translational studies, and expanded access data. Lastly, future directions for MF treatment are discussed, including ruxolitinib-based combination therapies. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 40 | 56% |
Canada | 2 | 3% |
United Kingdom | 2 | 3% |
India | 1 | 1% |
Lithuania | 1 | 1% |
Poland | 1 | 1% |
Germany | 1 | 1% |
Montenegro | 1 | 1% |
Argentina | 1 | 1% |
Other | 2 | 3% |
Unknown | 20 | 28% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 38 | 53% |
Scientists | 23 | 32% |
Practitioners (doctors, other healthcare professionals) | 7 | 10% |
Science communicators (journalists, bloggers, editors) | 4 | 6% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 15 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Lecturer | 1 | 7% |
Student > Postgraduate | 1 | 7% |
Other | 1 | 7% |
Student > Doctoral Student | 1 | 7% |
Unknown | 11 | 73% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 3 | 20% |
Biochemistry, Genetics and Molecular Biology | 1 | 7% |
Business, Management and Accounting | 1 | 7% |
Nursing and Health Professions | 1 | 7% |
Unknown | 9 | 60% |